Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
12-15-2021

Multicenter randomized phase II trial of atezolizumab with or
without cobimetinib in biliary tract cancers
Mark Yarchoan
John Hopkins University

Andrea Wang-Gillam
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Yarchoan, Mark; Wang-Gillam, Andrea; and et al, ,"Multicenter randomized phase II trial of atezolizumab
with or without cobimetinib in biliary tract cancers." Journal of clinical investigation. 131,24. . (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11239

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Multicenter randomized phase II trial of atezolizumab with or
without cobimetinib in biliary tract cancers
Mark Yarchoan, … , Gregory B. Lesinski, Nilofer S. Azad
J Clin Invest. 2021;131(24):e152670. https://doi.org/10.1172/JCI152670.
Clinical Medicine

Immunology

Oncology

MEK inhibitors have limited activity in biliary tract cancers (BTCs) as monotherapy but are hypothesized to enhance
responses to programmed death ligand 1 (PD-L1) inhibition.
This open-label phase II study randomized patients with BTC to atezolizumab (anti–PD-L1) as monotherapy or in
combination with cobimetinib (MEK inhibitor). Eligible patients had unresectable BTC with 1 to 2 lines of prior therapy in
the metastatic setting, measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status less
than or equal to 1. The primary endpoint was progression-free survival (PFS).
Seventy-seven patients were randomized and received study therapy. The trial met its primary endpoint, with a median
PFS of 3.65 months in the combination arm versus 1.87 months in the monotherapy arm (HR 0.58, 90% CI 0.35–0.93, 1tail P = 0.027). One patient in the combination arm (3.3%) and 1 patient in the monotherapy arm (2.8%) had a partial
response. Combination therapy was associated with more rash, gastrointestinal events, CPK elevations, and
thrombocytopenia. Exploratory analysis of tumor biopsies revealed enhanced expression of antigen processing and
presentation genes and an increase in CD8/FoxP3 ratios with combination treatment. Patients with higher baseline or
lower fold […]
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BACKGROUND. MEK inhibitors have limited activity in biliary tract cancers (BTCs) as monotherapy but are hypothesized to
enhance responses to programmed death ligand 1 (PD-L1) inhibition.
METHODS. This open-label phase II study randomized patients with BTC to atezolizumab (anti–PD-L1) as monotherapy or
in combination with cobimetinib (MEK inhibitor). Eligible patients had unresectable BTC with 1 to 2 lines of prior therapy in
the metastatic setting, measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status less than or
equal to 1. The primary endpoint was progression-free survival (PFS).
RESULTS. Seventy-seven patients were randomized and received study therapy. The trial met its primary endpoint,
with a median PFS of 3.65 months in the combination arm versus 1.87 months in the monotherapy arm (HR 0.58, 90%
CI 0.35–0.93, 1-tail P = 0.027). One patient in the combination arm (3.3%) and 1 patient in the monotherapy arm (2.8%)
had a partial response. Combination therapy was associated with more rash, gastrointestinal events, CPK elevations,
and thrombocytopenia. Exploratory analysis of tumor biopsies revealed enhanced expression of antigen processing and
presentation genes and an increase in CD8/FoxP3 ratios with combination treatment. Patients with higher baseline or lower
fold changes in expression of certain inhibitory ligands (LAG3, BTLA, VISTA) on circulating T cells had evidence of greater
clinical benefit from the combination.
CONCLUSION. The combination of atezolizumab plus cobimetinib prolonged PFS as compared with atezolizumab
monotherapy, but the low response rate in both arms highlights the immune-resistant nature of BTCs.
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Introduction

Biliary tract cancers (BTCs) are cancers arising from the biliary
epithelial cells and are historically subcategorized anatomically
as intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer. The incidence of BTCs is increasing, paralleling global trends in etiologic risk factors such as obesity and the metabolic syndrome, as well as improved awareness
and diagnostic expertise (1–3). Most patients have an advanced
stage at diagnosis, and outcomes are generally poor. Patients
receiving systemic therapy including the standard frontline therapy for unresectable BTC with gemcitabine plus cisplatin have
1
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Figure 1. Consort diagram.

a modest median overall survival (OS) of less than 1 year (4). A
subset of patients with BTC have potentially actionable molecular alterations such as FGFR2 fusions or rearrangements or IDH1
mutations and may benefit from treatment with molecularly targeted therapies (5, 6). The benefit of chemotherapy in the second
line setting is limited (7–10), underscoring the need for additional
treatment options for these patients.
The mitogen-activated protein kinase (MAPK) cascade is a
critical pathway for cell proliferation, and dysregulation of this
pathway is a hallmark of BTC (11–14). Mitogen/extracellular signal–regulated kinase (MEK) is a key intermediary component
of the MAPK pathway, and is an attractive target in principle for
therapeutic intervention in BTCs (15). MEK inhibitors have thus
far demonstrated some limited single agent activity in unselected BTCs (16–19). Similarly, immune checkpoint inhibitors (ICIs)
targeting programmed cell death protein 1 (PD-1) or its ligand,
PD-L1, have some limited activity in BTCs as monotherapy, with
response rates of approximately 6% to 11% in the largest reported prospective clinical trials, all single-arm studies (20–23). The
development of novel therapeutic combinations that can extend
the clinical benefit of ICIs to immunologically resistant tumors
such as BTCs remains a significant challenge.
MEK inhibitors have shown immunomodulatory effects and
substantial efficacy when combined with PD-1 and PD-L1 inhibitors in preclinical models of colon cancer, breast cancer, and melanoma (24–26). Targeting of the MAPK pathway through MEK
inhibition is hypothesized to modulate the tumor immune microenvironment (TME) through effects on tumor cells and direct
effects on immune cells, resulting in enhanced major histocompatibility complex class I (MHC-1) expression, PD-L1 expression,
and CD8+ T cell infiltration (25, 27–32). Although acceptable safety
and promising clinical activity was observed in initial phase I studies combining a MEK inhibitor plus PD-L1 inhibition with notable
clinical responses in colorectal cancer, this treatment combina2

tion recently failed to show compelling immune activity in a confirmatory phase III clinical study in colorectal cancer (33). Here
we report the results of a multicenter randomized phase II trial of
atezolizumab, an inhibitor of PD-L1, as monotherapy or in combination with the MEK inhibitor cobimetinib in BTCs.

Results

Patients and treatment. From February 2018, to October 2018, 86
participants were assessed for eligibility, of whom 77 were randomized and received treatment with atezolizumab monotherapy (n = 39) or atezolizumab plus cobimetinib (n = 38) at the NCI’s
Experimental Therapeutics Clinical Trials Network (ETCTN)
sites in the United States (Figure 1). Baseline demographic and
disease characteristics were similar between the 2 groups of randomized patients and are shown in Table 1. In total, 43 patients
(55.8%) had intrahepatic cholangiocarcinoma, 15 patients
(19.5%) had extrahepatic cholangiocarcinoma, and 19 patients
(24.7%) had gallbladder cancer. Most patients (61.0%) had 1 prior
regimen in the metastatic setting, whereas 39.0% had 2 prior systemic regimens in the metastatic setting. One participant in each
study arm had known mismatch repair deficiency (MMRd), and
no other patients had a known tumor mutation burden (TMB) of
greater than 10 mutations/Mb.
Clinical activity. The study met its primary endpoint, demonstrating a significantly longer PFS for patients in the combination
treatment than for those in the single treatment group (HR 0.58,
90% CI 0.35–0.93), P = 0.027 by a 1-sided, stratified log rank test).
An unstratified Kaplan-Meier plot is shown in Figure 2, and the 4-,
6-, and 12-month PFS for each study arm are shown in Supplemental Table 1. The median PFS for single and combination therapies
was 1.87 months and 3.65 months, respectively. The 4-month PFS
rate for the combination and monotherapy arms were 44.6% and
9.4%, respectively. The 6-month PFS rates were 22.3% and 9.4%,
and the 12-month PFS rates were 13.4 and 0%, for the combination
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Table 1. Baseline demographic and clinical characteristics of the
study patients
Tumor type
Extrahepatic cholangiocarcinoma (EHC)
Intrahepatic cholangiocarcinoma (IHC)
Gallbladder cancer (GBC)
Age, years
<50
50 to 70
>70
Sex
Female
Male
ECOG performance status
0
1
Race and ethnicity
White, not Hispanic
Hispanic
Black
Asian
Not reported
Prior therapies
1
2
MSI-H/MMRd
Positive
Negative or unknown
Mutations
Known KRAS mutation
Known IDH1 mutation
Known FGFR2 mutation
Known TP53 mutation
Known CDKN2A/B mutation
CA19-9
Elevated (>37 U/mL)
Not elevated
Unknown

Single, n = 39

Combination, n = 38

7
21
11

8
22
8

1
28
10

4
24
10

27
12

21
17

16
23

8
30

28
4
5
2
0

27
7
2
1
1

23
16

24
14

1
38

1
37

7
1
2
5
3

8
3
4
6
5

24
13
2

26
10
2

and monotherapy arms, respectively. In an unplanned, post hoc
analysis, there was a suggestion that the benefit observed for combination therapy was specific to intrahepatic cholangiocarcinoma.
This group of patients achieved a median PFS of 4.44 months on
combination therapy, whereas all other groups had median PFS of
1.71 months to 2.07 months regardless of treatment intervention.
A Kaplan-Meier plot stratified by primary disease site is shown in
Supplemental Figure 1.
In total, 36 patients in the monotherapy arm of the study and
30 patients in the combination arm of the study were evaluable
for response. The evaluable population included patients removed
from study prior to the first radiographic evaluation time point for
clinical progression or death from tumor progression. Among evaluable patients, 1 patient (2.8%) had an objective response in the
monotherapy arm and 1 patient (3.3%) had an objective response
in the combination arm. Disease control as demonstrated by par-

tial response plus stable disease was seen in 46.7% versus 30.6%
of patients treated with cobimetinib plus atezolizumab versus
atezolizumab alone, respectively; this difference was not statistically significant (P = 0.21). Response Evaluation Criteria in Solid
Tumors version 1.1 (RECIST 1.1) responses for all subjects who had
RECIST 1.1 evaluable scans are shown in Figure 3, and objective
responses for all evaluable patients are summarized in Table 2.
The 2 responders in our study included a patient with gallbladder cancer treated with atezolizumab monotherapy and a
patient with intrahepatic cholangiocarcinoma treated with combination therapy. These responses were both durable; the monotherapy patient response lasted approximately 10 months and
the combination therapy response is ongoing more than 2 years
after starting therapy. No molecular information was available for
the responder with gallbladder cancer, whereas the patient with
intrahepatic cholangiocarcinoma had known FGFR2, PIK3CA,
and TP53 mutations. One patient per treatment arm had known
MMRd, of whom neither responded to study therapy. The patient
with MMRd receiving monotherapy had progressive disease as
a best response to therapy, whereas the patient with MMRd randomized to the combination treatment arm was removed for intolerance prior to the first tumor evaluation.
Fifty patients (64.9%) had an elevated CA19-9 at study baseline, and CA19-9 levels were followed routinely for this subset of
patients. A waterfall plot of maximum CA19-9 decline on study
therapy for all subjects with an elevated CA19-9 at baseline is
shown in Supplemental Figure 2. Among patients with an elevated
CA19-9 at baseline, a decrease of 30% or more was observed in
4 of 24 patients (16.7%) in monotherapy arm and 7 of 26 patients
(26.9%) in the combination arm.
At the time of final analysis, 68 of 77 subjects had died. OS was
not different between the groups, though the study was not powered for this endpoint (P = 0.410 by 1-sided, log-rank test, stratified by tumor site). As shown in Supplemental Figure 3, median
survival by treatment group and primary tumor location strata varied widely (95–234 days).
Safety. All patients in either treatment arm who received at least
1 dose of study drug were included in the safety analysis. Treatment-related adverse events (TRAEs) that were reported in more
than 10% of patients in either treatment arm, as well as all treatment
related grade 3 or higher events, are shown in Table 3. The combination of cobimetinib and atezolizumab was associated with a higher
frequency of some adverse events than atezolizumab monotherapy,
including rash, pruritus, dry mouth, diarrhea, nausea or vomiting,
thrombocytopenia, and CPK elevations. Most of these events were
grade 1 to 2 and expected toxicities of cobimetinib.
TRAEs of any grade occurred comparably in both arms, affecting 33 subjects (84.6%) in the monotherapy arm and 33 subjects
(86.8%) in the combination treatment arm. Similarly, treatment-related grade 3 events occurred in 15 patients (38.5%) in the monotherapy arm and 17 patients (44.7%) in the combination arm. There were
no treatment-related grade 4 or grade 5 events in either treatment
arm. There were 13 deaths on study that were all determined to be
unrelated to study treatment. Most were related to disease progression (n = 12) or to sepsis in the setting of disease progression (n = 1).
Dose interruptions due to AEs occurred in 3 patients (7.9%)
in the combination treatment arm and 4 patients (10.3%) in the
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Nanostring PanCancer Immune Profiling Panel (Figure 4). As
compared with atezolizumab monotherapy, there was a trend
toward higher expression of antigen-processing and presentation genes, including TAP-associated glycoprotein (TAPBP),
immunoproteasome expression (proteasome subunit beta
type-8, PSMB8), and human leukocyte antigen (HLA) in the
combination arm, as well as enhanced expression of interferon signaling pathway member interferon-induced transmembrane protein 2 (IFITM2). While these differences are exploratory in nature, they support the idea that cobimetinib may
invigorate antitumor immunity in the TME and are in broad
agreement with preclinical models of MEK inhibition (26, 34).
Correlative analysis of cryopreserved PBMCs from patients
was conducted in an exploratory manner to assess T cell–
focused biomarkers and relationship to clinical outcome measures and treatment. For this analysis, we focused on differences in biomarkers attributable to the combination treatment
versus monotherapy by incorporating an interaction effect.
These data are summarized in Table 4. At baseline, patients in
the combination arm with a higher than median percentage of
LAG3+ CD8+ T cells (HR = 0.43, P = 0.035) had better OS than
in the monotherapy arm, while more TIM3+ CD4+ T cells (OR
= 4.8, P = 0.033) were indicative of more favorable response
Figure 2. Unstratified Kaplan-Meier plot of PFS for atezolizumab monotherapy (Arm A) and atezolizumab plus cobimetinib (Arm B).
by RECIST in the combination arm versus the monotherapy
arm. These biomarkers, however, were not significant predictors of better survival or clinical response at baseline when data
monotherapy arm. Dose reductions of cobimetinib occurred in
from all patients, regardless of treatment arm, were compiled for
6 patients (15.8%) in the combination arm. A total of 4 patients
analysis. In addition to assessing biomarkers at baseline, we also
(10.3%) receiving atezolizumab monotherapy and 8 patients
evaluated fold-change in cell percentages from baseline to cycle
(21.1%) receiving combination therapy with cobimetinib plus
2 day 1 (C2D1). This approach revealed that patients in the combiatezolizumab discontinued therapy due to AEs. Although there
nation arm with a decrease in several T cell–focused biomarkers
were twice as many discontinuations in the combination arm
had better OS. These included decreases in LAG3+ (HR = 0.36,
as the monotherapy arm due to AEs, neither inverse KaplanP = 0.024) and BTLA+ (HR = 0.31, P = 0.014) CD4+ T cells. ComMeier analysis nor Fisher’s exact test for study discontinuation
plementing these data was the observation that patients in Arm
rate due to adverse events was significant (P = 0.22). Although
B with a decrease in VISTA+ CD8+ T cells (HR = 0.23, P = 0.004)
most patients who discontinued combination therapy due to AEs
from baseline to C2D1 had significantly longer PFS. Because our
had multiple drug-related AEs that may have prompted discontinsubgroup analysis indicated the benefit of combination therapy
uation, nausea, vomiting, and diarrhea were the most common
might be limited to the intrahepatic subset, we also looked to see if
AEs reported by these patients.
this group had baseline differences in the expression of inhibitory
Biomarker analysis. Biopsies were mandated when feasible for
T cell checkpoints that were associated with evidence of greater
all subjects at baseline and at approximately day 21 of study therapy.
clinical benefit from the combination across the entire study popNine patients in each treatment arm had paired pretreatment and
ulation. However, we found no difference in the expression of
on-treatment biopsies, although tumor tissue was limited on some
LAG3 or TIM3 on T cells at baseline in this subgroup.
of these specimens. The randomized nature of the study enabled
us to interrogate the additive effects of MEK inhibition with cobiDiscussion
metinib on the tumor immune microenvironment by immunohisThis multicenter, open-label, randomized phase II trial of patients
tochemistry (IHC) in a subset of patients. Prior human serial biopwith advanced BTC met its primary endpoint, showing an
sy studies have reported that MEK inhibition can increase CD8+ T
improvement in PFS when cobimetinib was added to atezolizumab as compared with atezolizumab monotherapy. These data need
cell infiltration and antigen expression. However, CD8+ T cell and
to be interpreted in the context of a rapidly evolving treatment
human leucocyte antigen (HLA) expression were highly variable
landscape, with recent reports of 5-FU plus oxaliplatin (9) or 5-FU
across the samples analyzed. PD-L1 expression was negative in the
plus liposomal irinotecan (35) as second line treatment options
majority of samples and did not increase with therapy on either
for unselected BTC, and the development of multiple targeted
treatment arm. We did observe an increase in the CD8+ cytotoxic
therapies for the subsets of patients with potentially actionable
T cells to FoxP3 T regulatory cell ratio in the combination therapy
molecular alterations (5, 6, 36, 37). The safety of the atezolizumab
arm relative to the single treatment arm (Supplemental Figure 4).
plus cobimetinib combination was consistent with the toxicity proWe also explored differences between the combination and
file of the 2 individual drugs and with the prior experience of this
monotherapy treatment arms by RNA at day 21 using the nCounter
4
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Figure 3. Best response by RECIST 1. 1 among the evaluable patients
treated with atezolizumab monotherapy and atezolizumab plus cobimetinib. (A) Monotherapy. (B) Combination therapy.

combination in other tumor types (32, 33). Although some treatment-related adverse events were more common in the combination treatment arm, the study drugs predominantly had nonoverlapping adverse event profiles and were tolerable in combination.
This study is, to our knowledge, the largest randomized study
of immune checkpoint–based therapy for patients with BTC
reported to date, and builds upon other studies demonstrating
the limited clinical activity of ICIs as monotherapy in this disease
(20–23). Similarly, although MAPK pathway activation is common
in BTC, MEK inhibitors have shown only modest activity as monotherapy (16–19, 38) or in combination with chemotherapy (19).
This study was conducted because of preclinical research indicating the potential for synergy between MEK inhibition and systemic immunotherapies (25, 27–32). While our study did provide
evidence that MEK inhibitors may have some benefit in the context of systemic immunotherapy for BTCs, whether the modest
PFS benefit observed in our study reflects additive effects of the
individual therapies or true synergy resulting from MEK immunomodulation of the tumor microenvironment is unclear.
We did not observe an absolute increase in CD8+ T cell infiltration with combination therapy, as reported previously in a study of
cobimetinib monotherapy (32), but we did observe an increase in
CD8+ T cells to FoxP3+ T regulatory cell ratio in the combination
arm as compared with the monotherapy arm. The ratio of CD8+/

FoxP3+ Tregs within tumors are hypothesized to be prognostic
as well as predictive of responses to immunotherapy in a variety
of cancer settings (39–41). Our data provide initial evidence that
MEK inhibitors are immunomodulatory in BTC and augment
antitumor T cell immunity and/or inhibit immunosuppressive
axes within the tumor microenvironment. The observation of
enhanced expression of multiple genes involved antigen-processing and presentation in the present study is also consistent with
preclinical studies (26, 34). We also observed that patients with
higher baseline expression or smaller fold changes in the expression of multiple inhibitory ligands (LAG3, BTLA, VISTA) on circulating T cells had evidence of greater clinical benefit from the
combination. This work is hypothesis generating, but suggests the
possibility that the reversal or prevention of T cell exhaustion is
a key mechanism of systemic MEK inhibition immunomodulation, as previously shown in preclinical models (26, 34). Overall,
these clinical trial biomarkers suggest that MEK inhibitor therapy
modulated the response to anti–PD-L1 immunotherapy and was of
benefit for some patients. The small number of adequate biopsies
available for correlative analysis, and incomplete molecular information for the majority of patients, were significant limitations of
the present study.
The low response rate observed in the combination arm of the
study indicates that the observed changes to the TME were insufficient to cause tumor regression in the vast majority of patients
and highlights the immune-resistant nature of BTC. While MEK
inhibitors may augment antigen presentation and protect against
T cell exhaustion, they may also impair T cell priming and activation, which may limit the efficacy of this combination and provides a rationale for combining these agents with a T cell agonist
(26, 34, 42–44). Preclinical models support the efficacy of MEK
inhibitors plus PD-L1 inhibitors plus T cell costimulatory agents
(42–44). The hypothesis that the addition of a costimulatory agent
can restore T cell function when added to MEK inhibition plus
PD-L1 inhibitors is being explored in a follow-on randomized
study of cobimetinib, atezolizumab, and the CD27 T cell agonist
varlilumab in BTCs, conducted through our multi-institutional

Table 2. Objective response summary for evaluable patients
Response, n (%)
Complete response (CR)
Partial response (PR)
Stable disease (SD)
Progressive disease (PD)
Rate of objective response (CR+PR)
n (%)
Rate of disease control (CR+PR+SD)
n (%)

J Clin Invest. 2021;131(24):e152670 https://doi.org/10.1172/JCI152670

Single, n = 36

Combination, n = 30

0
1 (2.8)
10 (27.8)
25 (69.4)

0
1 (3.3)
13 (43.3)
16 (53.3)

1 (2.8)

1 (3.3)

11 (30.6)

14 (46.7)
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Table 3. Treatment-related AEs
Arm A (atezolizumab monotherapy)
Any grade
Grade 3
No. of patients
%
No. of patients
%
Cardio-renal
Edema
Hypertension
Hypokalemia
Hyponatremia
Myocarditis
Noncardiac chest pain
NSTEMI
Constitutional
Dehydration
Fatigue
Fever
Dermatologic
Rash
Pruritus
Endocrine
Hypercalcemia
Hyperglycemia
Thyroid dysfunction
Gastrointestinal
Abdominal pain
Anorexia
Colitis
Diarrhea
Dry mouth
Elevated liver function tests
Esophagitis
Nausea or vomiting
Small bowel obstruction
Hematologic
Anemia
Febrile neutropenia
Neutropenia or lymphopenia
Thrombocytopenia
Neurological
Dizziness
Headache
Meningitis (noninfectious)
Mental status changes
Syncope or vasovagal
Other
CPK elevation
Infusion reaction

Arm B (cobimetinib plus atezolizumab)
Any grade
Grade 3
No. of patients
%
No. of patients
%

1
1
2
6
1
1
1

2.6
2.6
5.1
15.4
2.6
2.6
2.6

0
1
0
1
1
1
1

0.0
2.6
0.0
2.6
2.6
2.6
2.6

4
4
1
4
2
0
0

10.5
10.5
2.6
10.5
5.3
0.0
0.0

0
0
1
1
1
0
0

0.0
0.0
2.6
2.6
2.6
0.0
0.0

1
15
8

2.6
38.5
20.5

1
0
0

2.6
0.0
0.0

4
16
10

10.5
42.1
26.3

2
1
0

5.3
2.6
0.0

2
0

5.1
0.0

0
0

0.0
0.0

19
7

50.0
18.4

2
0

5.3
0.0

1
2
6

2.6
5.1
15.4

1
1
0

2.6
2.6
0.0

1
4
3

2.6
10.5
7.9

1
0
0

2.6
0.0
0.0

5
7
2
11
0
10
0
8
1

12.8
17.9
5.1
28.2
0.0
25.6
0.0
20.5
2.6

1
2
2
0
0
1
0
1
1

2.6
5.1
5.1
0.0
0.0
2.6
0.0
2.6
2.6

1
4
1
17
6
12
1
19
0

2.6
10.5
2.6
44.7
15.8
31.6
2.6
50.0
0.0

0
0
1
5
0
3
1
3
0

0.0
0.0
2.6
13.2
0.0
7.9
2.6
7.9
0.0

7
0
7
4

17.9
0.0
17.9
10.3

1
0
1
0

2.6
0.0
2.6
0.0

10
1
8
14

26.3
2.6
21.1
36.8

3
1
3
1

7.9
2.6
7.9
2.6

3
1
1
3
0

7.7
2.6
2.6
7.7
0.0

0
0
1
0
0

0.0
0.0
2.6
0.0
0.0

6
2
0
1
2

15.8
5.3
0.0
2.6
5.3

0
1
0
1
2

0.0
2.6
0.0
2.6
5.3

0
5

0.0
12.8

0
1

0.0
2.6

6
2

15.8
5.3

0
0

0.0
0.0

Treatment-related AEs occurring in more than 10% of patients in either treatment arm, and all treatment-related grade 3 events. There were no treatmentrelated grade 4 or grade 5 events in either treatment arm. Rash, pruritus, dry mouth, diarrhea, nausea or vomiting, thrombocytopenia, and CPK elevations
were more common in the combination treatment arm (cobimetinib plus atezolizumab).

collaborative group within the NCI’s ETCTN (ClinicalTrials.gov
identifier: NCT04941287).
In summary, this randomized phase II study met its primary endpoint, indicating that the combination of cobimetinib and
atezolizumab may improve PFS and has a manageable safety profile. However, objective response rates were low in both treatment
6

groups, and we did not observe an increase in OS with the combination group. Due to the open-label nature of the study, we cannot
exclude the possibility that the benefit in PFS with combination
therapy was due to biases in assessment of progression rather than
differences in clinical activity between the study groups. Our finding that the benefit of combination therapy was specific to intra-
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Figure 4. Exploratory gene expression profiling. Tumor biopsies obtained at approximately treatment day 21 revealed differences in the expression
of multiple genes in the combination treatment arm versus the monotherapy arm. Enhanced expression of genes involved in antigen processing and
presentation (including TAP-associated glycoprotein [TAPBP], proteasome subunit beta type-8 [PSMB8], and human leukocyte antigen [HLA]) as well as
an increase in interferon signaling pathway member interferon-induced transmembrane protein 2 (IFITM2) in the combination arm, are consistent with
preclinical models of MEK inhibition. Quality control assessment and data normalization were performed using the default settings for positive controls
and the housekeeping genes in nSolver Analysis Software (NanoString Technologies) without P value adjustment, n = 6 samples per group.

hepatic cholangiocarcinoma in an unplanned post hoc analysis is
hypothesis generating and warrants further investigation. Intrahepatic cholangiocarcinoma has unique molecular altercations not
found in other anatomically defined subsets of BTC (45), and may
respond distinctly to MEK inhibition. Immunotherapy combinations including cobimetinib plus atezolizumab warrant additional
investigation in BTC, potentially as a basis for added novel combinatorial immunotherapy approaches.

Methods

Patients and eligibility criteria. At the time that the study was initiated, no treatment had ever conclusively shown benefit in second line
treatment of cholangiocarcinoma (7) and treatment guidelines did not
provide a recommendation for second line therapy. Eligible patients
had received at least 1 and not more than 2 prior lines of systemic
therapy in the metastatic setting. In addition, eligible patients were at
least 18 years of age, had an ECOG performance status score of 0 or
1, and had pathologically confirmed intrahepatic cholangiocarcinoma,
extrahepatic cholangiocarcinoma, or gallbladder carcinoma. Patients
with ampullary carcinoma were excluded. Eligible patients also had
measurable disease according to RECIST 1.1 and had adequate hematologic, hepatic, renal, and cardiac function. Patients with prior treat-

ment with a PD-1 or PD-L1 inhibitor or MEK inhibitor, a history of
autoimmune disease or treatment with systemic immunosuppressive
medications, or uncontrolled intercurrent illness were excluded. Due
to the potential for drug interactions with cobimetinib, patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 enzymes were also ineligible.
Randomization and treatment. Patients were randomly assigned
in a 1:1 ratio to receive atezolizumab 840 mg i.v. every 2 weeks (Arm
A), or cobimetinib 60 mg daily (21 days on/7 days off) plus atezolizumab 840 mg i.v. every 2 weeks (Arm B). Randomization was stratified after the screening phase according to the site of disease: (a)
gallbladder cancer; (b) intrahepatic; and (c) extrahepatic cholangiocarcinoma. Randomization was performed centrally and implemented through a web-based response system (Theradex Interactive Web
Response System). For reporting of race and ethnicity, all classifications were made by the investigators, and demographic options were
defined by the investigators.
The study treatment was continued until patients withdrew consent, developed unacceptable adverse effects, were not candidates for
further treatment in the judgment of the investigator, or developed
progression not meeting criteria for continuation past progression.
Treatment past progression was allowed for patients on both treat-
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Prep RNA protocol. RNA was analyzed both on the
Nanodrop 2000 and the Agilent 2100 Bioanalyzer.
RNA was run on the NanoString Human Pan Cancer Immune Profiling Panel. Samples were analyzed
Clinical endpoint
Biomarker
Hazard ratio
P value
using Nanostring nSolver 4.0 software. All RNA
Best responseA
CD4+ TIM3+ above the median at baseline
4.80 (1.14–20.27)
0.033
analyses were exploratory in nature, and reported
CD8+ LAG3+ above median at baseline
0.43 (0.20–0.94)
0.035
OSB
without correction for multiple comparisons.
+
+
0.36 (0.14–0.87)
0.024
CD4 LAG3 fold-change at C2D1 below the median
+
+
Peripheral blood was drawn prior to admin0.31 (0.12–0.79)
0.014
CD4 BTLA fold-change at C2D1 below the median
B
+
+
istration
of cobimetinib and/or atezolizumab at
CD8 VISTA fold-change at C2D1 below the median
0.23 (0.08–0.63)
0.004
PFS
baseline,
cycle
1 day 15, and cycle 2 day 1. PeripherA
Logistic regression with estimated odds ratio and 95% CI for comparison between Arm B and
al
blood
mononuclear
cells (PBMCs) were collectB
Arm A. Cox proportional hazard mode with estimated hazard ratio and 95% CI for comparison
ed
by
density
gradient
centrifugation as described
between Arm B and Arm A.
(47). Cryopreserved PBMCs underwent flow cytometric analysis for frequency of T cell subsets
and for expression of ICI molecules. PBMCs were
stained with anti–CD45-PerCP, anti–CD3-BV510, anti–CD4-PE/
ment arms, but only in cases of clinical benefit and absence of signs
Cy5, anti–CD8-APC/Cy7, anti–LAG3-AF700, anti–BTLA-PE/Cy7,
and symptoms of unequivocal progression, as assessed by the invesanti–VISTA-APC, and anti–TIM3-SB600. Antibodies used for PBMC
tigator. Treatment discontinuation was mandated on radiographic
staining are shown in Supplemental Table 2. Immune cell subsets were
progression at any subsequent evaluation. No dose reductions were
defined as: CD4+ T cells CD3+/CD4+, CD8+ T cells CD3+/CD8+, Th1
permitted for atezolizumab, but cobimetinib dose reductions were
cells CD3+/CD4+/tBet+, Th2 cells CD3+/CD4+/GATA3+, and Th17 cells
permitted in 20 mg increments for adverse events (i.e., grade ≥ 2;
CD3+/CD4+/RORγt+. ICI checkpoint molecules were assessed on both
see the study protocol). Patients experiencing intolerance to 1 of the
CD4+ and CD8+ T cells. PBMCs were fixed and permeabilized using
2 therapies in the combination study arm were permitted to continue
the eBioscience FoxP3/Transcription Factor Fixation/Permeabilizacobimetinib or atezolizumab monotherapy.
tion kit (Invitrogen). Data were acquired using a Cytek Aurora flow
Study endpoints. The primary objective of the trial was to detercytometer (Cytek Biosciences).
mine whether the combination of cobimetinib and atezolizumab
Statistics. With PFS as the primary endpoint, we planned to enroll
yields clinically compelling antitumor activity measured as PFS. The
82 patients with metastatic cholangiocarcinoma, with the goal of accruprimary endpoint of PFS was defined as the duration of time from date
ing at least 76 evaluable subjects. PFS within each treatment arm was
of randomization to time of progression or death. PFS was assessed by
summarized using Kaplan-Meier plots, and compared between groups,
the treating investigator according to RECIST 1.1. Tumor assessments
under the assumption of Cox proportional hazards, using the stratified
were obtained at baseline and approximately every 8 weeks while on
log-rank test to account for tumor site. We estimated that this design
study regardless of treatment arm. The evaluable population for the
yielded a 90% power at a 1-sided type I error rate of 5% assuming a
primary study endpoint included all subjects who had completed at
difference in median PFS between the arms of 2 months (2 months vs.
least 1 dose of therapy and had at least 1 follow-up scan or came off of
4 months), and assuming that 71 events would occur among 76 patients
study treatment for clinical progression prior to the first follow-up scan
over the study period. An interim analysis was planned when half the
(i.e., clinical progression). Patients removed from study for clinical or
required PFS events were observed (35). The trial would be stopped
radiographic progression prior to the first restaging scan were considearly for futility if the P value from the log-rank statistic was greater
ered to have had progressive disease as a best response to study therathan 0.5 (i.e., the PFS is worse for study Arm B than for study Arm A).
py for objective response rate. The analysis was stratified by the site of
Descriptive statistics were used to summarize data for each indidisease as described above. Additional secondary endpoints included
vidual biomarker at baseline and follow-up time points. The change
safety, objective response rate (ORR, assessed by RECIST 1.1) and OS.
at the follow-up time from baseline was calculated as the fold-change
Immune profiling of tumor and blood biospecimens. Patients with
between the 2 time points. All those biomarker measurements were
tumor that was amenable to biopsy underwent core biopsies at study
further compared between 2 treatment arms using Student’s t test. The
baseline and at cycle 1 day 21 (+/– 5 days). The biopsies were paraffin
association with clinical outcomes was explored using Cox proportionembedded and used to assess the effect of treatment arm on changes
al hazard model for time-to-event outcomes (e.g., OS or PFS) or logistic
in the tumor immune microenvironment. Staining of multiple immune
regression model for binary outcome (e.g., best response via RECIST).
markers by IHC was conducted in a Central Reference Clinical LaboThe biomarker value at baseline or its fold-change at a follow-up time
ratory Improvement Amendments Laboratory, and analysis of immune
point were further dichotomized by the median value noted above
cell populations was performed as previously described (46). Analysis of
versus below-median for all available patients regardless of treatment
PD-L1 and HLA expression was performed manually by a single hepagroup. The interaction effect between a dichotomized biomarker and
tobiliary pathologist who was blinded to treatment arm and clinical outtreatment groups were tested in Cox and logistic regression model, in
comes. RNA from patient biopsies were extracted using Qiagen AllPrep
which we compared treatment arms (Arm B: cobimetinib + atezolizumDNA/RNA. Large pieces of tissue were first ground using Thermo Fishab vs. Arm A: atezolizumab alone) inside each stratum by a biomarker.
er Scientific 15 mL closed tissue grinder (catalog 02-542-09). RLT bufA significant interaction term indicates there is differential patient’s
fer was added and the lysate was pipetted into a Qiashredder spin colresponse or outcome in treatments given their biomarker status. Such
umn (Qiagen, catalog 79656). The lysate was transferred to an AllPrep
a biomarker is also referred to as a predictive biomarker. We used the
RNA column (Qiagen) and purified following the manufacturer’s All-

Table 4. Biomarker correlative analyses in subgroups defined by biomarkers for OS,
PFS, and best response
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same strategy for all available biomarkers collected, but only reported
the ones that held significant interaction P < 0.05.
Study approval. The study was approved by the NCI’s Cancer Therapy Evaluation Program (CTEP) Institutional Review Board as well as the
IRB or ethics committee at each participating institution, and was conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonization Guidelines for
Good Clinical Practice. All patients provided written informed consent.
The trial was registered under ClinicalTrials.gov as NCT03201458.
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